Telomere length in Israeli patients with fibrotic ILD
Part of Lungs & breathing clinical trials.
This study looks at the length of telomeres (a part of your DNA) in people with fibrotic interstitial lung disease (ILD) in Israel. It aims to understand how telomere length relates to this condition and may help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You need to be able to sign a consent form to take part.
- Your chest CT scan must show signs of lung scarring (called honeycombing or traction bronchiectasis).
- Your lung disease should not be caused by sarcoidosis.
- You cannot have had a lung transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether using a home monitoring program helps people with pulmonary fibrosis track their condition. It aims to make care easier and catch changes early.
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
This study looks at genetic differences in people with idiopathic pulmonary fibrosis (a lung scarring condition with no known cause). It may help researchers understand what influences the disease and guide future treatment options.
This study looks at how to find and treat fibrotic interstitial lung disease (a condition where lung tissue becomes scarred and stiff) as early as possible. It may help people with this type of lung disease get better care.
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
This study follows patients with chronic lung scarring (fibrosing interstitial lung disease) who are in the intensive care unit for severe breathing failure. It aims to better understand their condition and care, which may help improve future treatments.
Hear when a new Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.